FACT-219

N/A

Report date: 2025/06/27 17:33:42

Base Information

Drug NameFACT-219

Drug Alias NameFACT-219

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLarge B Cell LymphomaRheumatic Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesFactor Bioscience Inc

China Registration ClassN/A

Develop Information

Active CompaniesFactor Bioscience Inc

Inactive CompaniesN/A

Active IndicationsLarge B Cell LymphomaRheumatic Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A